NEUROIMUNOLOGICKY USTAV SLOVENSKEJAKADEMIA VIED

Their core work

NIU SAV (Neuroimmunology Institute, Slovak Academy of Sciences) is a specialist research institute studying the intersection of immunology and neurodegenerative diseases, with particular expertise in the structural and molecular biology of disease-associated proteins. Their most recent EU-funded work centres on tau protein — the pathological aggregate implicated in Alzheimer's disease and related tauopathies — using high-resolution structural techniques including solid-state NMR, solution NMR, and cryo-electron microscopy to understand how tau misfolds and interacts with other proteins. Earlier, the institute contributed to pan-European coordination of research agendas under the Joint Programming Initiative on Neurodegenerative Diseases (JPND), signalling engagement beyond the lab bench into research governance. They operate as a focused research contributor within large international consortia rather than as a project lead.

What they specialise in

How they've shifted over time

In their first H2020 project (2015), the institute worked at the research-policy level: mapping national programmes, aligning research agendas, and supporting the sustainability of the JPND initiative — the kind of coordination work that requires domain authority but produces strategy documents rather than lab data. By 2020 their focus had shifted sharply to mechanistic, atomic-resolution science: tau misfolding, cryo-EM, and NMR spectroscopy. The trajectory is clear — from broad neurodegenerative disease governance toward deep structural biology of a single high-value therapeutic target.

NIU SAV is moving toward high-resolution mechanistic research on tau and related aggregating proteins, making them an increasingly relevant partner for drug discovery consortia targeting Alzheimer's and tauopathy therapeutics.

How they like to work

NIU SAV has never coordinated an H2020 project — both participations are as a consortium partner, which is consistent with a specialist institute that brings specific technical capability rather than project management infrastructure. Despite only two projects, they have engaged with 28 distinct partners across 20 countries, suggesting they are sought out for their expertise and integrate well into large, geographically diverse consortia. There is no evidence of repeated partnership with the same organisations, indicating broad network openness rather than closed collaboration circles.

Despite a small project portfolio, NIU SAV has built a notably wide network — 28 unique partners spanning 20 countries — almost certainly through the large MSCA-RISE and coordination action consortia they joined. Their geographic reach is genuinely European and extends globally through JPND's international alignment work.

What sets them apart

NIU SAV occupies an unusual niche: they combine immunological expertise with atomic-resolution structural biology tools (NMR, cryo-EM) focused on neurodegeneration — a combination that is far less common than either discipline alone. As part of the Slovak Academy of Sciences, they bring the credibility of a national academy institution to consortia that need Eastern European scientific representation alongside genuine technical depth. For Alzheimer's-focused drug discovery or diagnostic consortia, they offer direct access to structural data on tau protein interactions that few institutes in the region can match.

Highlights from their portfolio

• InterTAU
  The largest-funded project in their portfolio (EUR 492,200), it directly targets tau protein — one of the most commercially significant therapeutic targets in Alzheimer's drug development — using a multi-method structural biology approach that includes cryo-EM and NMR.
• JPsustaiND
  Participation in a pan-European Joint Programming coordination action demonstrates the institute's recognized authority in the neurodegenerative disease field beyond their own lab's output.